Three days ago, the Acting Attorney General moved state-licensed medical cannabis from Schedule I to Schedule III. Adult-use treatment is unchanged pending the broader DEA hearing scheduled for June 29, 2026.
The Acting Attorney General issued an administrative order under the Controlled Substances Act (21 USC § 811) moving two specific categories of marijuana from Schedule I to Schedule III. The mechanism is administrative scheduling, not legislation — no act of Congress, no FDA approval of a new drug, no change to the federal definition of marijuana itself.
Two categories now sit in Schedule III: FDA-approved drug products containing marijuana, and marijuana subject to a qualifying state medical marijuana license. Everything else stays in Schedule I — adult-use cannabis sold under a Type 10 retailer license, untested or unlicensed cannabis, and synthetically derived THC. A California operator selling exclusively to medical patients under their DCC license now sits inside a Schedule III activity for federal purposes; the same operator’s adult-use sales do not.
The June 29, 2026 DEA administrative hearing is the next decision point. The DOJ has ordered the DEA to consider rescheduling all marijuana — including adult-use — with a final rule possible by late 2026 absent litigation. Until then, the two-category split announced on April 22 stands.
“Two categories of marijuana are removed from Schedule I and placed in Schedule III, effective upon publication.”
The April 22 action sits at the end of a multi-step administrative process that began with the Department of Health and Human Services in 2023. The next milestone — the DEA hearing on broader rescheduling — is still ahead.
HHS recommendation to reschedule to III
DEA public comment period
DEA notice of proposed rulemaking
DOJ Schedule III order — medical only
DEA hearing on broader rescheduling (pending)
The April 22 order is a federal-tax and federal-banking event for one slice of California operators. For the rest, it changes the conversation more than the numbers.
IRC § 280E reaches only Schedule I and II controlled substances. State-licensed medical cannabis is now Schedule III, so ordinary deductions are restored on the medical line on a prospective basis.
Adult-use sales remain Schedule I federally. § 280E continues to disallow rent, payroll, marketing, and professional services on that revenue until the June 29 hearing decides otherwise.
Medical-only operators present a stronger margin profile to lenders and depositories. FDIC-insured access still waits on the SAFER Banking Act, which has not passed.
Schedule III is not federal legalization. Moving California cannabis across a state line remains a 21 USC § 841 trafficking offense regardless of medical status.
The action items below are sequenced for the operator who wants to be positioned correctly before the June 29 hearing. Every tax-related step is framed around coordination with retained CPA and tax counsel; none of this page is tax advice.
Coordinate with your CPA on a clean dataset. Medical-segment revenue is now the variable that matters most for federal-return planning, and the CDTFA history is the cleanest source.
Dual-track Type 10 retailers need bright-line allocation policies for 2026 forward. Coordinate with your CPA and retained tax counsel on methodology — the IRS will scrutinize allocation in early years.
Treasury has been encouraged but not required to address retroactive relief for medical operators. Protective filings on prior years preserve optionality if guidance opens the door.
Medical-only operators with restored deductions present differently to specialty banks and credit unions. The cap table, the deposit history, and the projected post-280E margin are the three documents to refresh.
State medical licensees may submit a DEA registration application within 60 days of the order to qualify for an expedited process. Coordinate with retained regulatory counsel before filing — this is a strategy decision, not an administrative one.
The hearing on broader rescheduling begins June 29, 2026 and must conclude by July 15, 2026. A final rule could publish by late 2026. Subscribe to the Federal Register docket and assign one team member to monitor it weekly.
Federal scheduling sits at 21 USC § 812 (the schedule definitions) and 21 USC § 841 (penalties for trafficking). Federal tax sits at IRC § 280E, which only reaches Schedule I and II substances and is the reason the April 22 order matters at all. The rescheduling authority itself is 21 USC § 811. California’s framework sits at BPC 26050 (license types), AB 195 (the cultivation tax elimination, July 1, 2022), AB 564 (the 15% retail-collected excise effective Oct 1, 2025 through June 30, 2028), and RTC § 34010–34021.5 (the Cannabis Tax Law). Together they describe the layered regime that the federal medical carve-out now sits inside.
We coordinate with your retained CPA and tax counsel on the calls that need a privileged opinion, and own the regulatory-strategy work in between.
